Aspiro Therapeutics CEO to Attend BIO CEO & Investor Conference 2025
Tucson, Arizona / January 27, 2025 — Aspiro Therapeutics, a pioneering biopharmaceutical company dedicated to developing innovative treatments for obstructive lung diseases, announced that its CEO, James Lovgren, will attend the BIO CEO & Investor Conference 2025. The conference, hosted by the Biotechnology Innovation Organization (BIO), is one of the industry’s premier events, bringing together […]
Aspiro Therapeutics Joins Biotechnology Innovation Organization (BIO)
Tucson, AZ / Jan. 22, 2025–Aspiro Therapeutics, a pioneering biotech company dedicated to developing advanced treatments for obstructive lung diseases, is excited to announce its membership with the Biotechnology Innovation Organization (BIO.org). By joining the world’s largest trade association representing the biotechnology industry, Aspiro reaffirms its commitment to advancing groundbreaking science and fostering collaboration across […]
Aspiro Therapeutics and University of Arizona Awarded Follow-On Funding from the Flinn Foundation
Tucson, AZ / January 13, 2025 – Aspiro Therapeutics, in collaboration with the University of Arizona, is honored to announce it has been awarded follow-on funding through the Flinn Foundation Seed Grants to Promote Translational Research program. This additional $100,000 funding underscores the team’s continued progress in developing innovative therapies for obstructive lung diseases. The follow-on […]
Aspiro Therapeutics to Present at Biotech Showcase™ 2025
Pioneering a Novel Disease-Modifying Therapy for Obstructive Lung Disease San Francisco, CA / Jan. 8 2025—Aspiro Therapeutics, an innovator developing an advanced, disease-modifying therapy that targets obstructive lung diseases, today announced that its CEO, James Lovgren, will present at Seed Showcase™, part of Biotech Showcase 2025. The presentation, “A Novel Therapy to Treat Obstructive […]
Aspiro Therapeutics Acknowledges Co-Founder Dr. Julie Ledford’s Flinn Foundation Seed Grant for Pioneering Research in Respiratory Health
Tucson, AZ / May 1, 2024 – Aspiro Therapeutics proudly highlights the foundational work of co-founder Dr. Julie Ledford, whose research, funded by a Flinn Foundation Seed Grant awarded in June 2023, played a key role in Aspiro’s formation and scientific direction. Awarded through her role at the University of Arizona, Dr. Ledford’s research focuses on […]
CC16 drives VLA-2-dependent SPLUNC1 expression
Rationale: CC16 (Club Cell Secretory Protein) is a protein produced by club cells and other non-ciliated epithelial cells within the lungs. CC16 has been shown to protect against the development of obstructive lung diseases and attenuate pulmonary pathogen burden. Despite recent advances in understanding CC16 effects in circulation, the biological mechanisms of CC16 in pulmonary epithelial […]
Circulating CC16 and Asthma: a Population-Based, Multi-Cohort Study from Early Childhood Through Adult Life
Rationale: Club cell secretory protein (CC16) is an antiinflammatory protein highly expressed in the airways. CC16 deficiency has been associated with lung function deficits, but its role in asthma has not been established conclusively. Objectives: To determine 1) the longitudinal association of circulating CC16 with the presence of active asthma from early childhood through adult life and 2) whether […]
β-Arrestin-biased proteinase-activated receptor-2 antagonist C781 limits allergen-induced airway hyperresponsiveness and inflammation
Background and purpose: Asthma is a heterogenous disease strongly associated with inflammation that has many different causes and triggers. Current asthma treatments target symptoms such as bronchoconstriction and airway inflammation. Despite recent advances in biological therapies, there remains a need for new classes of therapeutic agents with novel, upstream targets. The proteinase-activated receptor-2 (PAR2) has long […]
CC16 Binding to α4β1 Integrin (VLA-4) Protects Against Mycoplasma pneumoniae Infection
Rationale CC16 (club cell secretory protein) is a pneumoprotein produced predominantly by pulmonary club cells. Circulating CC16 is associated with protection from the inception and progression of the two most common obstructive lung diseases (asthma and chronic obstructive pulmonary disease). Objectives Although exact mechanisms remain elusive, studies consistently suggest a causal role of CC16 in mediating antiinflammatory […]
CC16 Deficiency in the Context of Early Life Mycoplasma pneumoniae Infection Results in Augmented Airway Responses in Adult Mice
Studies have shown that club cell secretory protein (CC16) plays important protective roles in the lungs, yet its complete biological functions are unclear. We devised a translational mouse model in order to investigate the impact of early life infections, in the context of CC16 deficiency, on lung function in adult mice. CC16 sufficient (WT) and […]